Crossmark

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crossref DOI link: https://doi.org/10.1186/s12885-019-5308-y

Published Online: 2019-02-01

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Heynckes, Sabrina

Daka, Karam

Franco, Pamela

Gaebelein, Annette

Frenking, Jan Hendrik

Doria-Medina, Roberto

Mader, Irina

Delev, Daniel

Schnell, Oliver

Heiland, Dieter Henrik http://orcid.org/0000-0002-9258-3033
Funding

Funding for this research was provided by:

Müller-Fahnenberg Stiftung

Familie-Medhorn Stiftung

German Cancer Society (Seeding Grand TII)
License Information

Text and Data Mining valid from 2019-02-01
More Information

Article History

Received: 23 July 2018

Accepted: 17 January 2019

First Online: 1 February 2019

Ethics approval and consent to participate

: The local ethics committee of the University of Freiburg approved data evaluation, imaging procedures and experimental design (protocol 100,020/09 and 5565/15). The methods were carried out in accordance with the approved guidelines. Written informed consent was obtained.

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.